Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Osimertinib plus selumetinib shows promise in advanced NSCLC
The combination of osimertinib plus selumetinib exhibits antitumour activity in patients with MET-negative, EGFRm advanced nonsmall cell lung cancer (NSCLC), with the safety profile consistent with the reported safety data for the drugs, according to data from the small open-label, phase Ib study.
Osimertinib plus selumetinib shows promise in advanced NSCLC
11 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
10 Oct 2022
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
Bronchodilators, used in the treatment of chronic obstructive pulmonary disease (COPD), did not appear to benefit individuals with a history of smoking and respiratory symptoms who did not have airflow obstruction, results of the US-based RETHINC* study showed.
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
08 Oct 2022
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
07 Oct 2022
Dapagliflozin prevents worsening heart failure, CV death
Dapagliflozin is a safe treatment to reduce the risk of worsening heart failure (HF) or cardiovascular death both in patients with and without history of recent HF hospitalization, a study has shown.
